3 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
Follow Celularity Incorporated: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM) rhIL-2, PNK-007 - Multiple Myeloma | Phase 1 | Completed | Celularity Incorporated | 15 | 2017-01-05 | 2020-07-22 |
| Study of PDA-002 in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcers PDA-002 - Peripheral Arterial Disease, Diabetic Foot Ulcer | Phase 1 | Completed | Celularity Incorporated | 15 | 2013-05-23 | 2026-06-04 |
| A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease PDA001, Vehicle Controlled Placebo - Crohns Disease | Phase 1 | Completed | Celularity Incorporated | 14 | 2013-03-01 | 2018-03-01 |
Crohn Disease (1) · Diabetic Foot (1) · Diarrhea (1) · Fistula (1) · Multiple Myeloma (1) · Neoplasms, Plasma Cell (1) · Peripheral Arterial Disease (1)
United States (3)
Monica E Luchi, MD (1) · Solveig Ericson, MD (1)